{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT03680677",
            "orgStudyIdInfo": {
                "id": "UPCC 06718"
            },
            "secondaryIdInfos": [
                {
                    "id": "831340",
                    "type": "OTHER",
                    "domain": "U Penn IRB"
                }
            ],
            "organization": {
                "fullName": "Abramson Cancer Center at Penn Medicine",
                "class": "OTHER"
            },
            "briefTitle": "Frailty Phenotype Assessments to Optimize Treatment Strategies for Older Patients With Hematologic Malignancies",
            "officialTitle": "Prospective Analysis of Frailty Phenotype Assessments to Optimize Treatment Strategies for Older Patients With Hematologic Malignancies",
            "therapeuticArea": [
                "Oncology and Hematology",
                "Other"
            ],
            "study": "frailty-phenotype-assessments-to-optimize-treatment-strategies-for-older-patients-with-hematologic-malignancies"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-07",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2018-09-21",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2025-06-22",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2025-11",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2018-09-20",
            "studyFirstSubmitQcDate": "2018-09-20",
            "studyFirstPostDateStruct": {
                "date": "2018-09-21",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-07-24",
            "lastUpdatePostDateStruct": {
                "date": "2024-07-25",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Abramson Cancer Center at Penn Medicine",
                "class": "OTHER"
            }
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": false,
            "isFdaRegulatedDevice": false,
            "isUsExport": false
        },
        "descriptionModule": {
            "briefSummary": "The purpose of this research study is to determine if frailty assessments can be used to predict how well patients aged 60 years and older will do after chemotherapy, CAR T-cell therapy, or allogeneic stem cell transplant."
        },
        "conditionsModule": {
            "conditions": [
                "Leukemia, Acute",
                "MDS"
            ]
        },
        "designModule": {
            "studyType": "OBSERVATIONAL",
            "patientRegistry": false,
            "designInfo": {
                "observationalModel": "COHORT",
                "timePerspective": "PROSPECTIVE"
            },
            "enrollmentInfo": {
                "count": 20,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Cancer Directed Therapy or Best Supportive Care",
                    "description": "Cancer-directed therapy with intensive regimens, clinical trial, hypomethylating agent, hypomethylating agent combinations, targeted agents alone, or best supportive care",
                    "interventionNames": [
                        "Other: Cancer-directed Therapy or Best Supportive Care",
                        "Diagnostic Test: Frailty Assessment"
                    ]
                },
                {
                    "label": "Transplant",
                    "description": "Bone marrow or peripheral blood graft (BMT) or CAR T-cell therapy",
                    "interventionNames": [
                        "Procedure: Bone Marrow or Peripheral Blood Graft (BMT)",
                        "Diagnostic Test: Frailty Assessment"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "PROCEDURE",
                    "name": "Bone Marrow or Peripheral Blood Graft (BMT)",
                    "description": "Patient receives bone marrow or peripheral blood graft (BMT) on or off protocol.",
                    "armGroupLabels": [
                        "Transplant"
                    ]
                },
                {
                    "type": "OTHER",
                    "name": "Cancer-directed Therapy or Best Supportive Care",
                    "description": "Cancer-directed therapy with intensive regimens (\"7+3,\" Vyxeos, clofarabine, or similar), clinical trial, hypomethylating agent (azacitidine or decitabine), hypomethylating agent combinations (i.e. with venetoclax, sorafenib, enasidenib, ivosidenib, midostaurin, gilteritinib, or other targeted agent), targeted agents alone (i.e. enasidenib, ivosidenib, gilteritinib, midostaurin, etc.), or supportive care.",
                    "armGroupLabels": [
                        "Cancer Directed Therapy or Best Supportive Care"
                    ]
                },
                {
                    "type": "DIAGNOSTIC_TEST",
                    "name": "Frailty Assessment",
                    "description": "Frailty is the vulnerability of older adults to adverse health outcomes in response to illness and iatrogenic stressors.",
                    "armGroupLabels": [
                        "Cancer Directed Therapy or Best Supportive Care",
                        "Transplant"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Non-Relapse Mortality (NRM) in Frail, Pre-Frail, and Non-Frail patients",
                    "description": "NRM will be defined as death without evidence of disease progression or relapse.",
                    "timeFrame": "1-month"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "NRM by Intensity of Treatment",
                    "description": "NRM of frail and pre-frail patients by intensity of treatment",
                    "timeFrame": "1-month and 6-month"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Eligibility Criteria Arm A:\n\n* Age 60 years or older.\n* New diagnosis of Acute Leukemia or MDS, or suspected diagnosis.\n* Able to consent to the study.\n\nEligibility Criteria Arm B:\n\n* Age 60 years or older with a hematologic malignancy.\n* Plan to undergo an allogeneic blood or marrow transplantation or CAR T-cell therapy.\n* Able to consent to the study.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "60 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ],
            "studyPopulation": "Two cohorts of patients will be included in this analysis.\n\nArm A will include patients 60 years of age and older with a new diagnosis of either acute leukemia or MDS who are being evaluated either in the outpatient or inpatient hematologic malignancies department at the University of Pennsylvania.\n\nArm B will include patients 60 years of age and older with a diagnosis of any hematologic malignancy being treated with cellular therapy including allogeneic blood or marrow transplantation or CAR T-cells.",
            "samplingMethod": "NON_PROBABILITY_SAMPLE"
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Shannon McCurdy, MD",
                    "role": "CONTACT",
                    "phone": "855-216-0098",
                    "email": "penncancertrials@emergingmed.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Shannon McCurdy, MD",
                    "affiliation": "Abramson Cancer Center",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "Abramson Cancer Center of the University of Pennsylvania",
                    "status": "RECRUITING",
                    "city": "Philadelphia",
                    "state": "Pennsylvania",
                    "zip": "19104",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 39.95233,
                        "lon": -75.16379
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "UNDECIDED"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000019337",
                    "term": "Hematologic Neoplasms"
                },
                {
                    "id": "D000073496",
                    "term": "Frailty"
                }
            ],
            "ancestors": [
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000010335",
                    "term": "Pathologic Processes"
                },
                {
                    "id": "D000009371",
                    "term": "Neoplasms by Site"
                },
                {
                    "id": "D000006402",
                    "term": "Hematologic Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M21314",
                    "name": "Hematologic Neoplasms",
                    "asFound": "Hematologic Malignancies",
                    "relevance": "HIGH"
                },
                {
                    "id": "M1175",
                    "name": "Frailty",
                    "asFound": "Frailty",
                    "relevance": "HIGH"
                },
                {
                    "id": "M10945",
                    "name": "Leukemia",
                    "relevance": "LOW"
                },
                {
                    "id": "M9490",
                    "name": "Hematologic Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "T170",
                    "name": "Acute Graft Versus Host Disease",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "BC15",
                    "name": "Blood and Lymph Conditions"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "browseLeaves": [
                {
                    "id": "M1680",
                    "name": "Sorafenib",
                    "relevance": "LOW"
                },
                {
                    "id": "M249656",
                    "name": "Venetoclax",
                    "relevance": "LOW"
                },
                {
                    "id": "M4673",
                    "name": "Azacitidine",
                    "relevance": "LOW"
                },
                {
                    "id": "M1697",
                    "name": "Decitabine",
                    "relevance": "LOW"
                },
                {
                    "id": "M242252",
                    "name": "Ivosidenib",
                    "relevance": "LOW"
                },
                {
                    "id": "M58265",
                    "name": "Gilteritinib",
                    "relevance": "LOW"
                },
                {
                    "id": "M353083",
                    "name": "Midostaurin",
                    "relevance": "LOW"
                },
                {
                    "id": "M1921",
                    "name": "Clofarabine",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "ANeo",
                    "name": "Antineoplastic Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}